Loss of Appetite in Adult Patients: Effectiveness and Safety of an Appetite Stimulating Medication in an Open-Label, Investigator-Initiated Study in India

Table 2

Medical history summary according to acute and chronic illness (safety population).

Medical heading term, n (%)	Overall (N = 50)
Acute illness	8 (16.0)
Acute febrile illness, loss of appetite, hyperlipidemia	1 (2.0)
Fever, loss of appetite, essential hypertension	1 (2.0)
Viral fever, loss of appetite	2 (4.0)
Viral fever, loss of appetite, allergic bronchitis	1 (2.0)
Viral fever, loss of appetite, arthritis	2 (4.0)
Viral fever, loss of appetite, hypothyroidism	1 (2.0)
Chronic illness	42 (84.0)
Allergic bronchitis, loss of appetite	1 (2.0)
Essential hypertension, loss of appetite	6 (12.0)
Hypothyroidism, loss of appetite	3 (6.0)
Hypothyroidism, loss of appetite, essential hypertension	1 (2.0)
Loss of appetite, essential hypertension	1 (2.0)
Type II diabetes mellitus, loss of appetite	11 (22.0)
Type II diabetes mellitus, loss of appetite, allergic bronchitis	3 (6.0)
Type II diabetes mellitus, loss of appetite, essential hypertension	7 (14.0)
Type II diabetes mellitus, loss of appetite, hypothyroidism	1 (2.0)
Vitamin B12 deficiency, loss of appetite	2 (4.0)
Vitamin D deficiency, loss of appetite	1 (2.0)
Vitamin D deficiency, loss of appetite	4 (8.0)
Vitamin D deficiency, loss of appetite, vitamin B12 deficiency	1 (2.0)

Safety population consisted of all patients who received at least one dose of the study medication.